Dice Molecules, a US-based biopharmaceutical developer backed by pharmaceutical firm Sanofi and life sciences real estate investment trust Alexandria Real Estate Equities, closed a $60m series C1 round yesterday.
RA Capital Management and Sands Capital co-led the round, which included Osage University Partners (OUP), Janus Henderson Investors, Deep Track Capital, Logos Capital, Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners and Asymmetry Capital.
Founded in 2014, Dice is working on a drug discovery platform for oral therapeutics aimed at chronic diseases in immunology and other areas.
The company’s lead product candidate is aimed at a range of autoimmune conditions and it has two preclinical assets targeting inflammatory bowel disease and idiopathic pulmonary fibrosis respectively.
The funding will support the advancement of all three candidates in addition to the expansion of Dice’s pipeline. It said it has now secured approximately $200m in funding.
Dice had completed an $80m series C round in January this year led by RA Capital and backed by Sanofi subsidiary Sanofi Ventures and Alexandria Venture Investments, on behalf of Alexandria Real Estate Equities – both existing investors.
OUP, Eventide, New Leaf, Soleus Capital, Driehaus Capital Management, Asymmetry Capital, Northpond Ventures, Sands Capital, Altitude Life Science Ventures and Agent Capital filled out the series C investors.
The original version of this article appeared on our sister site, Global University Venturing.
